Amarin Announces Completion of Dosing in a Fixed-Dose Combination Study With Vascepa(R) and a Leading Statin
December 17, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 17, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowance for U.S. Application 13/623,450 Related to Vascepa(R) and FDA Approved MARINE Indication
December 13, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 13, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
David Stack Appointed to Amarin Board of Directors
December 12, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Dec. 12, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Additional Vascepa(R) (icosapent ethyl) Supplier
December 11, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 11, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the development of therapeutics to improve...
Amarin Announces $100 Million Non-Equity Financing and Vascepa Sales Force Hiring While Continuing to Assess Strategic Alternatives
December 06, 2012 16:02 ET
|
Amarin Corporation plc
Steps Are Consistent With Amarin's Continuation of Its Strategy to Parallel Process Three Strategic Options
Conference Call Scheduled for Today, December 6th at 4:30 p.m. ET
BEDMINSTER,...
Amarin Announces U.S. Patent 8,324,195 Issuance for Vascepa(R)
December 04, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Dec. 4, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces U.S. Patent 8,318,715 Issuance for Vascepa(R)
November 27, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 27, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowance for U.S. Application 13/610,247 Related to Vascepa(R) and FDA Approved MARINE Indication
November 26, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 26, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces U.S. Patent 8,314,086 Issuance for Vascepa(R)
November 20, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J. and DUBLIN, Ireland, Nov. 20, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...
Amarin Announces Notification of Patent Allowance for U.S. Application 13/608,775 Related to Vascepa(R) and FDA Approved MARINE Indication
November 19, 2012 07:30 ET
|
Amarin Corporation plc
BEDMINSTER, N.J., and DUBLIN, Ireland, Nov. 19, 2012 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of...